Latanoprost

Generic Name: Latanoprost

Brand Names: Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₄₀O_₅

CAS Number: 130209-82-4

Unique Ingredient Identifier: 6Z5B6HVF6O

Background: Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...

Indication: Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...

Associated Conditions: Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)

Associated Therapies: -

Clinical Trials

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Xalatan
Drug: Travatan Z

First Posted Date: 2008-11-26

Last Posted Date: 2018-07-12

Lead Sponsor: Wills Eye

Target Recruit Count: 58

Registration Number: NCT00798694

Locations: 🇺🇸
Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States

Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure

Phase 4

Conditions: Glaucoma

Interventions: Drug: Xalatan+Cosopt
Drug: Xalatan

First Posted Date: 2008-11-24

Last Posted Date: 2008-11-25

Lead Sponsor: University of Turin, Italy

Target Recruit Count: 50

Registration Number: NCT00796198

Locations: 🇮🇹
University of Turin, Turin, Italy
🇮🇹
University of Siena, Siena, Italy
🇮🇹
University of Chieti, Chieti, Italy

and more 2 locations

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Phase 3

Completed

Conditions: Glaucoma

Interventions: Drug: latanoprost
Drug: Timolol

First Posted Date: 2008-07-16

Last Posted Date: 2021-02-03

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 139

Registration Number: NCT00716859

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Phase 4

Completed

Conditions: Application Site Pigmentation Changes
Glaucoma

Interventions: Drug: bimatoprost
Drug: latanoprost
Drug: travoprost

First Posted Date: 2008-06-26

Last Posted Date: 2016-01-18

Lead Sponsor: Summa Health System

Target Recruit Count: 89

Registration Number: NCT00705757

Locations: 🇺🇸
Arlington Eye Physicians, Arlington Heights, Illinois, United States
🇺🇸
Summa Health System, Akron, Ohio, United States

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Latanoprost

First Posted Date: 2008-03-31

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 600

Registration Number: NCT00647101

Locations: 🇫🇷
Pfizer Investigational Site, Wattrelos, France

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Phase 1

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: latanoprost

First Posted Date: 2008-03-19

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 47

Registration Number: NCT00638742

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

Comparison of Latanoprost Vs. Timolol

Phase 2

Terminated

Conditions: Glaucoma

Interventions: Drug: Latanoprost
Drug: Timolol

First Posted Date: 2007-12-24

Last Posted Date: 2023-12-21

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT00579969

Locations: 🇺🇸
UNMC Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Phase 2

Completed

Conditions: Glaucoma

Interventions: Drug: Latanoprost
Drug: Dorzolamide
Drug: Timolol

First Posted Date: 2007-12-13

Last Posted Date: 2023-10-24

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT00572936

Locations: 🇺🇸
University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

First Posted Date: 2007-04-25

Last Posted Date: 2008-07-29

Lead Sponsor: Alcon Research

Target Recruit Count: 150

Registration Number: NCT00465621

Locations: 🇺🇸
Atlanta, Atlanta, Georgia, United States

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

Not Applicable

Conditions: Open Angle Glaucoma

First Posted Date: 2007-02-27

Last Posted Date: 2007-03-01

Lead Sponsor: Advanced Glaucoma Specialists

Target Recruit Count: 30

Registration Number: NCT00440336

Locations: 🇺🇸
Advanced Glaucoma Specialist, Reading, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy